Haemonetics Corporation (HAE) Key Metrics
HAE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $5.38B
- Enterprise value
- $5.81B
- P/E (TTM)
- 57.1 10-yr median 67.5
- Forward P/E
- 20.3
- PEG ratio
- 1.69
- Price / sales
- 4.0 10-yr median 3.5
- Price / book
- 5.8 10-yr median 4.9
- EV / EBITDA
- 9.4 10-yr median 18.4
- Dividend yield
- —
- Beta
- 0.61
HAE key metrics, FY2017–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsHAE valuation Price multiples at each fiscal year-end price.
HAE returns How much profit the business earns on the capital it uses.
HAE per-share figures Results divided by the shares outstanding at year-end.
HAE financial health Debt, liquidity and how easily interest is covered.
HAE efficiency & capital use Working capital cycle and where the cash goes.
HAE valuation history
HAE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HAE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HAE cash returned to shareholders
HAE price vs earnings per share
HAE key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.67B | $3.22B | $4.39B | $4.26B | $3.25B | $5.69B | $5.16B | $4.63B | $3.91B | $2.09B |
| Enterprise value | $3.65B | $4.14B | $5.02B | $4.74B | $3.77B | $6.28B | $5.47B | $4.81B | $3.99B | $2.27B |
| P/E ratio | 27.4 | 19.2 | 37.3 | 36.9 | 74.8 | 71.6 | 67.5 | 84.2 | 85.9 | — |
| Price / sales | 2.0 | 2.4 | 3.4 | 3.6 | 3.3 | 6.5 | 5.2 | 4.8 | 4.3 | 2.4 |
| Price / book | 3.4 | 3.9 | 4.6 | 5.2 | 4.3 | 7.8 | 8.8 | 6.9 | 5.2 | 2.8 |
| Price / free cash flow | 10.2 | 22.6 | 30.5 | 26.1 | 42.9 | 79.3 | 47.2 | 114.9 | 26.9 | 25.0 |
| Price / operating cash flow | 9.1 | 17.7 | 24.1 | 15.6 | 18.8 | 52.3 | 32.6 | 29.1 | 17.8 | 13.1 |
| EV / sales | 2.7 | 3.0 | 3.8 | 4.1 | 3.8 | 7.2 | 5.5 | 5.0 | 4.4 | 2.6 |
| EV / EBITDA | 13.6 | 11.4 | 16.5 | 18.2 | 18.6 | 34.1 | 19.8 | 24.9 | 26.1 | 17.6 |
| EV / free cash flow | 14.0 | 29.1 | 34.9 | 29.1 | 49.7 | 87.5 | 50.0 | 119.3 | 27.4 | 27.1 |
| Earnings yield | 3.6% | 5.2% | 2.7% | 2.7% | 1.3% | 1.4% | 1.5% | 1.2% | 1.2% | −1.3% |
| Free cash flow yield | 9.8% | 4.4% | 3.3% | 3.8% | 2.3% | 1.3% | 2.1% | 0.9% | 3.7% | 4.0% |
| Dividend yield | — | — | — | 0.2% | — | — | 0.2% | 0.3% | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 6.6% | 7.0% | 0.1% | 1.9% | 2.3% | 0.0% | 3.6% | 3.7% | 2.6% | 0.0% |
| Share price at fiscal year-end | $56.36 | $63.55 | $85.35 | $82.75 | $63.22 | $111.01 | $99.66 | $87.48 | $73.16 | $40.57 |
| Per share | ||||||||||
| Revenue per share | $28.17 | $26.82 | $25.47 | $22.73 | $19.34 | $16.97 | $19.08 | $18.28 | $16.90 | $17.20 |
| Earnings per share | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | −$0.51 |
| Operating cash flow per share | $6.19 | $3.58 | $3.54 | $5.31 | $3.35 | $2.12 | $3.05 | $3.01 | $4.12 | $3.10 |
| Free cash flow per share | $5.50 | $2.81 | $2.79 | $3.17 | $1.48 | $1.40 | $2.11 | $0.76 | $2.72 | $1.62 |
| Cash per share | $5.18 | $6.05 | $3.48 | $5.53 | $5.05 | $3.75 | $2.65 | $3.20 | $3.37 | $2.71 |
| Book value per share | $16.82 | $16.18 | $18.68 | $15.91 | $14.59 | $14.26 | $11.33 | $12.62 | $14.06 | $14.35 |
| Tangible book value per share | −$6.50 | −$4.71 | −$0.22 | $1.48 | −$0.55 | −$1.95 | $4.70 | $6.22 | $7.19 | $6.82 |
| Dividends per share | — | — | — | $0.14 | — | — | $0.23 | $0.25 | $0.00 | $0.00 |
| Capex per share | $0.69 | $0.77 | $0.74 | $2.14 | $1.88 | $0.72 | $0.94 | $2.25 | $1.40 | $1.48 |
| Debt per share | $25.86 | $24.14 | $15.72 | $14.89 | $15.20 | $15.17 | $8.53 | $6.61 | $4.74 | $6.11 |
| Shares outstanding | 47.4M | 50.7M | 51.4M | 51.4M | 51.4M | 51.3M | 51.8M | 52.9M | 53.5M | 51.5M |
| Change in shares outstanding | −6.7% | −1.3% | −0.0% | +0.1% | +0.1% | −1.0% | −2.1% | −1.0% | +3.8% | +1.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 12.0% | 18.8% | 13.2% | 14.7% | 5.9% | 12.1% | 12.2% | 7.7% | 6.1% | −3.6% |
| Return on invested capital (ROIC) | 10.4% | 10.5% | 8.8% | 9.9% | 4.3% | 8.1% | 10.4% | 7.5% | 4.9% | −1.6% |
| Return on assets (ROA) | 4.0% | 7.2% | 5.7% | 6.1% | 2.4% | 5.1% | 6.0% | 4.4% | 3.7% | −2.1% |
| Return on tangible assets | 7.5% | 12.1% | 9.6% | 9.7% | 4.0% | 8.0% | 8.3% | 5.9% | 5.2% | −3.1% |
| Free cash flow margin | 19.5% | 10.5% | 11.0% | 13.9% | 7.6% | 8.2% | 11.1% | 4.2% | 16.1% | 9.4% |
| Income quality (OCF / net income) | 3.01 | 1.08 | 1.55 | 2.37 | 3.97 | 1.37 | 2.07 | 2.90 | 4.84 | — |
| Financial health | ||||||||||
| Total debt | $1.22B | $1.22B | $807.8M | $765.9M | $780.8M | $778.3M | $441.8M | $350.1M | $253.7M | $314.6M |
| Cash & short-term investments | $245.4M | $306.8M | $178.8M | $284.5M | $259.5M | $192.3M | $137.3M | $169.4M | $180.2M | $139.6M |
| Net debt | $979.1M | $918.0M | $629.0M | $481.4M | $521.3M | $586.0M | $304.5M | $180.8M | $73.5M | $175.1M |
| Debt / equity | 1.54 | 1.49 | 0.84 | 0.94 | 1.04 | 1.06 | 0.75 | 0.52 | 0.34 | 0.43 |
| Debt / assets | 0.51 | 0.50 | 0.37 | 0.40 | 0.42 | 0.43 | 0.35 | 0.27 | 0.21 | 0.25 |
| Net debt / EBITDA | 3.65 | 2.53 | 2.07 | 1.85 | 2.57 | 3.18 | 1.10 | 0.94 | 0.48 | 1.36 |
| Current ratio | 2.95 | 1.62 | 2.56 | 3.06 | 1.71 | 2.74 | 2.20 | 2.44 | 1.35 | 2.42 |
| Quick ratio | 1.87 | 0.99 | 1.50 | 2.03 | 1.05 | 1.46 | 1.21 | 1.62 | 0.94 | 1.58 |
| Interest coverage | 8.4 | 22.8 | 12.7 | 10.7 | 4.7 | 5.3 | 6.4 | 8.4 | 12.4 | -2.4 |
| Working capital | $552.3M | $356.9M | $468.5M | $517.9M | $313.8M | $440.1M | $328.8M | $340.4M | $136.5M | $298.9M |
| Invested capital | $1.78B | $1.74B | $1.59B | $1.30B | $1.27B | $1.32B | $891.6M | $848.6M | $825.9M | $914.7M |
| Tangible asset value | −$307.7M | −$239.2M | −$11.2M | $76.0M | −$28.1M | −$100.3M | $243.4M | $329.4M | $384.4M | $351.2M |
| Net current asset value | −$764.7M | −$695.1M | −$466.7M | −$347.1M | −$354.3M | −$394.7M | −$76.4M | −$30.8M | $36.3M | $10.9M |
| Graham number | $27.88 | $34.69 | $31.00 | $28.34 | $16.65 | $22.30 | $19.40 | $17.17 | $16.42 | — |
| Graham net-net per share | −$21.93 | −$19.49 | −$14.46 | −$11.05 | −$11.39 | −$12.46 | −$5.47 | −$3.81 | −$2.07 | −$3.04 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $7.0M | — | — | $12.0M | $13.4M | $0 | $0 |
| Share buybacks (net) | $175.0M | $225.0M | $5.9M | $75.0M | $75.0M | $0 | $175.0M | $160.0M | $100.0M | $0 |
| Dividend payout ratio | — | — | — | 6.1% | — | — | 15.7% | 24.4% | 0.0% | — |
| Dividends + buybacks / free cash flow | 67.2% | 158.0% | 4.1% | 50.4% | 99.0% | 0.0% | 170.9% | 430.2% | 68.7% | 0.0% |
| Capex / revenue | 2.5% | 2.9% | 2.9% | 9.4% | 9.7% | 4.3% | 4.9% | 12.3% | 8.3% | 8.6% |
| Capex / operating cash flow | 11.2% | 21.6% | 21.0% | 40.4% | 56.0% | 34.0% | 30.8% | 74.7% | 33.9% | 47.7% |
| Capex / depreciation | 0.29 | 0.34 | 0.39 | 1.18 | 0.99 | 0.44 | 0.44 | 1.09 | 0.84 | 0.85 |
| Stock-based compensation / revenue | 2.5% | 2.2% | 2.2% | 2.2% | 2.5% | 2.9% | 2.1% | 1.8% | 1.4% | 1.0% |
| R&D / revenue | 4.5% | 5.1% | 4.8% | 5.0% | 5.6% | 4.7% | 4.0% | 3.7% | 4.3% | 5.3% |
| SG&A / revenue | 33.2% | 31.0% | 32.1% | 32.0% | 33.4% | 30.3% | 26.9% | 30.8% | 35.0% | 34.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 57.4 | 54.9 | 53.8 | 52.9 | 52.7 | 61.4 | 64.7 | 63.4 | 61.4 | 63.8 |
| Days of inventory on hand | 207.6 | 213.9 | 176.2 | 184.7 | 243.0 | 244.8 | 169.4 | 117.8 | 125.3 | 130.5 |
| Days payables outstanding | 36.5 | 44.0 | 42.0 | 40.9 | 42.9 | 41.7 | 41.6 | 39.4 | 36.4 | 29.7 |
| Cash conversion cycle (days) | 228.5 | 224.8 | 188.0 | 196.7 | 252.8 | 264.5 | 192.4 | 141.9 | 150.2 | 164.6 |
| Receivables turnover | 6.36 | 6.65 | 6.79 | 6.90 | 6.92 | 5.95 | 5.64 | 5.76 | 5.95 | 5.72 |
| Payables turnover | 10.00 | 8.30 | 8.70 | 8.93 | 8.51 | 8.75 | 8.78 | 9.27 | 10.02 | 12.28 |
| Inventory turnover | 1.76 | 1.71 | 2.07 | 1.98 | 1.50 | 1.49 | 2.16 | 3.10 | 2.91 | 2.80 |
| Asset turnover | 0.55 | 0.59 | 0.63 | 0.62 | 0.54 | 0.56 | 0.78 | 0.77 | 0.73 | 0.69 |
| Average receivables | $209.8M | $204.6M | $192.9M | $169.3M | $143.5M | $146.4M | $175.1M | $168.1M | $152.0M | $154.9M |
| Average payables | $59.0M | $70.2M | $68.6M | $61.1M | $54.3M | $50.5M | $57.0M | $59.3M | $49.1M | $41.3M |
| Average inventory | $335.8M | $341.2M | $288.3M | $276.2M | $307.8M | $296.4M | $232.3M | $177.6M | $168.9M | $181.5M |
| Intangibles / total assets | 46.1% | 43.2% | 44.2% | 38.3% | 41.8% | 45.7% | 27.1% | 26.6% | 29.7% | 31.4% |
Computed from HAE's annual financial statements (latest annual report filed May 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HAE valuation and financial ratios
At the end of fiscal 2026 (March 31, 2026), Haemonetics traded at 27.4 times earnings, against a 10-year median of 67.5. Based on the latest twelve months, the trailing P/E is 57.1 and the forward P/E is 20.3. Haemonetics earned a return on equity of 12.0% and a return on invested capital of 10.4% in fiscal 2026. It ended the year with $1.2 billion of debt and $245.4 million in cash and short-term investments, net debt of $979.1 million. It returned $175.0 million to shareholders: $0 in dividends and $175.0 million in share buybacks, 67% of free cash flow. The share count fell 8.1% from 51.5M to 47.4M over 9 years.
See the HAE income statement, the HAE chart for price history, or the HAE stock overview for the latest quote and news.
HAE key metrics FAQ
What is Haemonetics's P/E ratio?
Haemonetics's trailing P/E ratio is 57.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 20.3. At the end of fiscal 2026 it was 27.4, compared with a 10-year median of 67.5.
What is Haemonetics's EV/EBITDA?
Haemonetics's enterprise value was 13.6 times EBITDA at the end of fiscal 2026 (enterprise value $3.6 billion, EBITDA $268.5 million); the current EV/EBITDA is 9.4.
What is Haemonetics's return on equity?
Haemonetics's return on equity (ROE) was 12.0% in fiscal 2026: net income of $97.3 million on average shareholders' equity of $808.6 million.
What is Haemonetics's ROIC?
Haemonetics's return on invested capital was 10.4% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Haemonetics have?
Haemonetics had total debt of $1.2 billion at the end of fiscal 2026, a debt-to-equity ratio of 1.54 and $979.1 million of net debt (3.65 times EBITDA).
Does Haemonetics buy back its shares?
Yes. Haemonetics spent $175.0 million on net share repurchases in fiscal 2026 Shares outstanding changed −6.7% over the year, to 47.4M..
What is Haemonetics's free cash flow yield?
Haemonetics generated $260.4 million of free cash flow in fiscal 2026, a free cash flow yield of 9.8% on its market value at year-end ($2.7 billion).
What is Haemonetics's current ratio?
Haemonetics's current ratio was 2.95 at the end of fiscal 2026: current assets were 2.95 times current liabilities.